<DOC>
	<DOCNO>NCT01732952</DOCNO>
	<brief_summary>This cross-sectional , non-interventional , observational study ass lipid profile patient take lipid-modifying drug ( i.e. , proportion patient achieve treatment goal accord national international lipid management guideline ) single visit physician outpatient basis 6 representative geo-economic region China : Northeast , North , East , South , Southwest , Northwest ; within region , three tier hospital : tier 3 ( primary teaching hospital ) , tier 2 ( secondary city level hospital ) , tier 1 ( community hospitals/health center ) . The investigator primarily cardiologist , endocrinologist , neurologist , gerontologist , internist , physician representative general population physician manage patient dyslipidemia and/or high risk cardiovascular event likely treat lipid-modifying drug . Demographic data , cardiovascular risk factor , history cardiovascular disease cardiovascular treatment document single visit patient clinical examination chart review . DYSIS-China part string epidemiological study share master protocol , conduct different country mainly Europe Canada . The analysis pool study include overall data cross-country comparison subject distinct protocol .</brief_summary>
	<brief_title>Dyslipidemia International Survey-China</brief_title>
	<detailed_description />
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>1 . Patient outpatient &gt; 45 year age 2 . Patient currently* treat statin 3 . Patient document fast lipid profile ( &gt; 1 lipid parameter within last 12 month ) perform lipidmodifying therapy least 3 month 4 . Patient agree participate study give informed consent . Patient already treat lipidmodifying drug visit . Patient lipidmodifying therapy initiated time visit must include . 1 . Patient currently participate clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>prevalence , lipid abnormality , CV risk</keyword>
</DOC>